Soligenix Inc. (NASDAQ: SNGX) recently shared updates on the clinical development of HyBryte(TM) (synthetic hypericin) during an investment webinar hosted by Allele Capital. The focus was on the ongoing confirmatory Phase 3 trial for cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin's lymphoma, and the promising interim results from an investigator-initiated study at the University of Pennsylvania. Under the leadership of Dr. Ellen Kim, the study revealed that 75% of the first eight patients who completed 18 weeks of treatment showed a greater than 50% reduction in disease severity.
HyBryte(TM), Soligenix's lead asset, is a topical therapy activated by visible light, designed to target early-stage mycosis fungoides, which constitutes nearly 90% of CTCL cases. The therapy's mechanism involves direct application to cancerous lesions on the skin, offering a novel approach to treating this challenging condition. Dr. Christopher Schaber, Soligenix's chairman, president, and CEO, emphasized the potential of HyBryte(TM) to transform the treatment landscape for CTCL, a disease that affects a significant number of patients worldwide.
The company anticipates releasing top-line results from the Phase 3 trial in the second half of 2026. This development is crucial for patients suffering from CTCL, as it represents a potential new treatment option with a favorable safety profile and ease of use. The progress of HyBryte(TM) underscores Soligenix's commitment to addressing unmet medical needs in rare diseases, positioning the company as a key player in the biopharmaceutical industry's efforts to innovate in oncology and dermatology.
For more information on Soligenix and its developments, visit https://ibn.fm/SNGX.
